

Attachment 5 – 510(k) Summary

1. Bisco, Inc.
1100 W. Irving Park Road
Schaumburg, IL 60193
847-534-6000
Contact: Kathryn B. Patterson, Regulatory Affairs Manager
Date Prepared: October 14, 1999
2. Device Trade Name: Light-Core™
Common/Usual Name: Translucent Core Build-up Composite
Classification Name: Filling Material
3. Predicate Device: Kuraray's Photo Core, K882006 (cleared June 13, 1988)
4. Light-Core is a translucent, fiber-reinforced, light-cured core build-up composite for use with a 4th or 5th generation adhesive system.
5. The intended use of Light-Core is:
 - Core build-up composite for use with a 4th or 5th generation adhesive system.
6. Light-Core possesses the same technological characteristics as the predicate device, Clearfil Photo Core. Below is a table which shows a side-by-side comparison of the technological characteristics of Light-Core and Clearfil Photo Core.

Characteristic	Light-Core	Clearfil Photo Core
Intended Use	Restoration where light-curing composite for core build-up is required.	Restoration where light-curing composite for core build-up is required.
Chemical Composition	Light-cured	Light-cured
Physical/Mechanical Properties	High flexural, compressive and tensile strengths. Flexural modulus similar to dentin.	High flexural, compressive and tensile strengths. Flexural modulus similar to dentin.
Biocompatibility	Non-toxic	Non-toxic
Depth of Cure	High	High
Physical Description	Light-cured, high-viscosity, translucent composite.	Light-cured, high-viscosity, translucent composite.
Handling Time (post-dispensing)	5 minutes	5 minutes



NOV 10 1999

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Ms. Kathryn B. Patterson
Regulatory Affairs Manager
Bisco, Inc.
1100 W. Irving Park Road
Schaumburg, IL 60193

Re: K993488
Trade Name: Light-Core™ (Translucent Core Build-up Composite)
Regulatory Class: II
Product Code: EBF
Dated: October 14, 1999
Received: October 15, 1999

Dear Ms. Patterson:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Pre-market Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in

the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4692. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,



Timothy A. Ulatowski
Director
Division of Dental, Infection Control
and General Hospital Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

K993488

Attachment 2 – Indications for Use

Indications for Use

510(k) Number (if known): K993488

Device Name: Light-Core™, Translucent Core Build-up Composite

Indications for Use:

- Core Build-up Composite for use with a 4th or 5th generation adhesive system.

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use X
Use _____
(Per 21 CFR 801.109)

OR Over-the-Counter

Susan Runner

(Optional Format 1-2-96)

(Division Sign-Off)
Division of Dental, Infection Control,
and General Hospital Devices
510(k) Number K993488

000002